Literature DB >> 27365386

Editorial Commentary: Where to Place the New Treatments for Clostridium difficile Infection?

Oliver A Cornely1, Maria J G T Vehreschild2.   

Abstract

Entities:  

Keywords:  Clostridium difficile; bezlotoxumab; fidaxomicin; recurrence; treatment pathway

Mesh：

Substances：

Year:  2016        PMID： 27365386      PMCID： PMC4996134          DOI： 10.1093/cid/ciw366

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  11 in total

1.  Fidaxomicin versus vancomycin for Clostridium difficile infection.

Authors:  Thomas J Louie; Mark A Miller; Kathleen M Mullane; Karl Weiss; Arnold Lentnek; Yoav Golan; Sherwood Gorbach; Pamela Sears; Youe-Kong Shue
Journal:  N Engl J Med       Date:  2011-02-03       Impact factor: 91.245

2.  Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial.

Authors:  Dale N Gerding; Thomas Meyer; Christine Lee; Stuart H Cohen; Uma K Murthy; Andre Poirier; Trevor C Van Schooneveld; Darrell S Pardi; Antonio Ramos; Michelle A Barron; Hongzi Chen; Stephen Villano
Journal:  JAMA       Date:  2015-05-05       Impact factor: 56.272

3.  Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.

Authors:  Stuart Johnson; Thomas J Louie; Dale N Gerding; Oliver A Cornely; Scott Chasan-Taber; David Fitts; Steven P Gelone; Colin Broom; David M Davidson
Journal:  Clin Infect Dis       Date:  2014-05-05       Impact factor: 9.079

4.  Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.

Authors:  Oliver A Cornely; Derrick W Crook; Roberto Esposito; André Poirier; Michael S Somero; Karl Weiss; Pamela Sears; Sherwood Gorbach
Journal:  Lancet Infect Dis       Date:  2012-02-08       Impact factor: 25.071

5.  Duodenal infusion of donor feces for recurrent Clostridium difficile.

Authors:  Els van Nood; Anne Vrieze; Max Nieuwdorp; Susana Fuentes; Erwin G Zoetendal; Willem M de Vos; Caroline E Visser; Ed J Kuijper; Joep F W M Bartelsman; Jan G P Tijssen; Peter Speelman; Marcel G W Dijkgraaf; Josbert J Keller
Journal:  N Engl J Med       Date:  2013-01-16       Impact factor: 91.245

6.  Treatment with monoclonal antibodies against Clostridium difficile toxins.

Authors:  Israel Lowy; Deborah C Molrine; Brett A Leav; Barbra M Blair; Roger Baxter; Dale N Gerding; Geoffrey Nichol; William D Thomas; Mark Leney; Susan Sloan; Catherine A Hay; Donna M Ambrosino
Journal:  N Engl J Med       Date:  2010-01-21       Impact factor: 91.245

7.  Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI).

Authors:  Brett A Leav; Barbra Blair; Mark Leney; Michael Knauber; Courtney Reilly; Israel Lowy; Dale N Gerding; Ciarán P Kelly; Kia Katchar; Roger Baxter; Donna Ambrosino; Deborah Molrine
Journal:  Vaccine       Date:  2009-11-24       Impact factor: 3.641

8.  Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence.

Authors:  Swati B Gupta; Vinay Mehta; Erik R Dubberke; Xuemei Zhao; Mary Beth Dorr; Dalya Guris; Deborah Molrine; Mark Leney; Mark Miller; Marilyne Dupin; T Christopher Mast
Journal:  Clin Infect Dis       Date:  2016-06-30       Impact factor: 9.079

9.  Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.

Authors:  Oliver A Cornely; Mark A Miller; Thomas J Louie; Derrick W Crook; Sherwood L Gorbach
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079

10.  Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection.

Authors:  Lauren Lapointe-Shaw; Kim L Tran; Peter C Coyte; Rebecca L Hancock-Howard; Jeff Powis; Susan M Poutanen; Susy Hota
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240
View more
  1 in total

Review 1.  Clinical Practice and Infrastructure Review of Fecal Microbiota Transplantation for Clostridium difficile Infection.

Authors:  Brendan J Kelly; Pablo Tebas
Journal:  Chest       Date:  2017-09-18       Impact factor: 9.410
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.